ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2025
Cutaneous larva migrans in Canadian travellers returning from the Caribbean: A 10-year surveillance analysis from CanTravNet.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous larva migrans (CLM) is one of the most common dermatoses affecting travellers to the tropics. Objective: To describe demographic and travel correlates of travellers returning to Canada from the Caribbean with CLM over a 10-year pre-pandemic period. Methods: Demographic and travel-related data on ill travellers encountered either during or after completion of their travel/migration and seen in any of eight CanTravNet sites from January 1, 2009, to December 31, 2018, with a final diagnosis of CLM were extracted and analyzed. During this time, access to first-line therapy, ivermectin, was available via Health Canada's Special Access Programme. Results: Of 17,644 travellers presenting to CanTravNet over the enrolment period, 328 (1.9%) returned from the Caribbean with CLM. The median age of travellers with CLM was 34 years (interquartile range: 25-50 years), with females accounting for 58% of cases. Ninety-five percent (n=313) travelled for tourism. Jamaica was the most common source country, with 216 cases (67%), followed by Barbados (n=27, 8%) and the Dominican Republic (n=23, 7%). Cases in 2018 were imported predominantly from Jamaica (n=58, 73%) and the Dominican Republic (n=12, 15%). Age, sex and purpose of travel were similar across years. The percentage of all imported cases of CLM that originated from the Caribbean increased from 9% in 2016 to 24.5% in 2018. Conclusion: Proportions and absolute numbers of CLM in travellers returning to Canada from the Caribbean are increasing. Improved awareness of this common dermatosis among physicians and travellers, as well as improved access to effective therapies, will reduce associated morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.